Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males and females~* Diagnosis of RRMS as defined by the revised (2005) McDonald Diagnostic Criteria for Multiple Sclerosis (MS).~* Signed inform consent prior to initiation of any study-mandated procedure.~Exclusion Criteria:~* A diagnosis of MS categorized as primary progressive or secondary progressive or progressive relapsing.~* Patients currently treated for an autoimmune disorder other than MS.~* Contraindications for MRI.~* Ongoing bacterial, viral, or fungal infection.~* History or presence of malignancy.~Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ACT-128800 Dose 1 (Type: EXPERIMENTAL): ACT-128800 Dose 1
- ACT-128800 Dose 2 (Type: EXPERIMENTAL): ACT-128800 Dose 2
- ACT-128800 Dose 3 (Type: EXPERIMENTAL): ACT-128800 Dose 3
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).